BI-836880 clinical trials
Also written BI 836880.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses BI-836880 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BI 836880
- 5
Studies by the year they started
5 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses BI-836880 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid TumoursCompletedPhase 1Boehringer IngelheimNCT03468426Written as BI 836880
- A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced CancerCompletedPhase 1Boehringer IngelheimNCT03972150Written as BI 836880
- Dose Finding Study of BI 836880 in Patients With Solid TumorsCompletedPhase 1Boehringer IngelheimNCT02674152Written as BI 836880
- Weekly BI 836880 in Patients With Advanced Solid TumorsCompletedPhase 1Boehringer IngelheimNCT02689505Written as BI 836880
- A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)CompletedPhase 1/2Boehringer IngelheimNCT03861234Written as BI 836880
Given beside what is tested · 3 — BI-836880 is usual care or a partner of the new treatment
- A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver CancerCompletedPhase 1Boehringer IngelheimNCT05249426Written as BI 836880
- Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid TumoursCompletedPhase 2Boehringer IngelheimNCT03697304Written as BI 836880
- A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal CancerWithdrawnPhase 2Boehringer IngelheimNCT04499352Written as BI 836880
Codes
What other systems call BI-836880 · ClinicalTrials.gg INT016867
- UNII (FDA) IS7N1X9TSWBI-836880One source FDA
- NCI Thesaurus C126644Anti-VEGF/ANG2 Nanobody BI 836880One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | IS7N1X9TSW | BI-836880 | One source FDA |
| NCI Thesaurus | C126644 | Anti-VEGF/ANG2 Nanobody BI 836880 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.